Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$72.86M+171.42%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Farquhar
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 843
- Beta
- 2.02
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 29.29
Financials
HTFL has only 11 quarterly periods on file — the charts below show the full history available.
Revenue
$72.86M+171.4%Net Income
$-11.51MEBITDA
$-11.48MFree Cash Flow
$-1.08MEPS (diluted)
$-0.13Shares Outstanding (diluted)
87.25M+36.6%Operating Expenses
$74.76MCash & Debt
$167.74MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $176.03M | $-116.79M | $-1.37 |
| 2024 | $125.81M | $-96.43M | $-1.53 |
| 2023 | $87.17M | $-95.66M | $-1.94 |
Valuation
HTFLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (16)
- News (RSS)seekingalpha·5d ago·Neutral
HeartFlow: A Post Q3 Assessment
View source ↗ - News (RSS)fool·8d ago·Negative
HeartFlow: 3 Key Takeaways for Long-Term Investors Operating losses are narrowing as revenue outpaces expenses, and the company's $253 million cash pile is meant to carry it until it turns cash-flow positive.
View source ↗ - Newsfool.com·9d ago·Neutral
HeartFlow: 3 Key Takeaways for Long-Term Investors Full-year 2026 revenue guidance raised to $262 million to $264 million. Plaque Analysis reduced major cardiovascular events by 34% at one year.
View source ↗ - News (RSS)fool·9d ago·Positive
HeartFlow (HTFL) Q3 2026 Earnings Call Transcript Plaque Analysis drove growth, but management flagged a flat Q4 pricing outlook.
View source ↗ - Newsdefenseworld.net·13d ago·Negative
Heartflow (NASDAQ:HTFL) Stock Rating Lowered by Wall Street Zen Read Heartflow (NASDAQ: HTFL) Stock Rating Lowered by Wall Street Zen at Defense World
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026 SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2026 after market close on Thursday, November 12, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on…
View source ↗ - News (RSS)investing·65d ago·Neutral
Heartflow Inc stock hits all-time high at 51.78 USD
View source ↗ - News (RSS)seekingalpha·71d ago·Neutral
HeartFlow, Inc. (HTFL) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow
View source ↗ - Newsfool.com·77d ago·Negative
HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High The sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85. The traded shares represent 13% of the equity stake held by the officer before the transaction.
View source ↗ - Newsglobenewswire.com·86d ago·Neutral
Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals FUSION trial presented at ESC and published in Journal of the American College of Cardi
View source ↗ - Newsglobenewswire.com·87d ago·Neutral
Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21st Annual Healthcare Conference. The fireside chat, which will include a slideshow presentation followed by a question-and-answer ses…
View source ↗ - Newsseekingalpha.com·98d ago·Neutral
HeartFlow: An Impressive MedTech Growth Play HeartFlow delivered a convincing Q2 with 48% sales growth and gross margins rising to 83%, driving strong market optimism. The company raised full-year revenue guidance to $246–$250 million, though the outlook appears conservative given recent momentum and sequential growth. Shares now trade at 13x sales, supported by accelerating topline growth, expanding plaque-related revenue, and commercial adoption of its non-invasive cardiac solution.
View source ↗ - Newsfool.com·100d ago·Negative
Why Heartflow Stock Soared Today Heartflow's AI-powered platform could save countless lives. The company is growing at an impressive clip.
View source ↗ - Newsseekingalpha.com·100d ago·Positive
HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·101d ago·Neutral
Heartflow Q2 Earnings Call Highlights Heartflow NASDAQ: HTFL reported second-quarter revenue of $64.1 million, up 48% from a year earlier, as growth in its Plaque Analysis offering, durable FFR-CT utilization and continued expansion of the coronary CT angiography, or CCTA, market supported results.
View source ↗ - Newszacks.com·101d ago·Neutral
HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago.
View source ↗
Earnings
Wed, Mar 17(in 4 months)
Consensus estimate $-0.09 per share
Typical surprise +36.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.03 vs $-0.10beat
- Thu, Aug 13$-0.07 vs $-0.13beat
- Thu, May 14$-0.16 vs $-0.19beat
- Wed, Mar 18$-0.12 vs $-0.19beat
- Wed, Nov 12$-0.27 vs $-0.20miss
- Fri, Sep 19$-0.06 vs $-0.21beat
Estimates and results for HTFL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HTFL officers and directors.
- Bought
- —
- Sold
- $25.9m
0 trades
36 trades
- Rogers Campbellsold
- Rogers Campbellsold
- Rogers Campbellsold
- Farquhar John C.m.sold
- Verghese Vikramsold
- Rogers Campbellsold
- Rogers Campbellsold
- Rogers Campbellsold
64 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HTFL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
